In the phase 2a PELICAN study (NCT03474042), ABBV-2737 demonstrated significant improvements compared to placebo in CF patients homozygous for F508del who were already receiving lumacaftor/ivacaftor, confirming its ability to enhance CFTR function in combination therapy. This evidence concerns the gene CFTR and cystic fibrosis.